INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsBusiness Wire • 05/17/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsBusiness Wire • 05/16/24
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of InvestorsBusiness Wire • 05/16/24
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial ResultsGlobeNewsWire • 05/13/24
Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's BoxSeeking Alpha • 05/10/24
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's DiseaseGlobeNewsWire • 05/09/24
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's DiseaseGlobeNewsWire • 04/29/24
Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to TradeZacks Investment Research • 04/24/24
Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?Zacks Investment Research • 04/08/24
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 04/02/24
Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in HumansGlobeNewsWire • 04/01/24
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a BetZacks Investment Research • 03/21/24
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's DiseaseGlobeNewsWire • 03/20/24
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's DiseaseGlobeNewsWire • 02/14/24
Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's ProspectsSeeking Alpha • 02/12/24
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's PortfolioGlobeNewsWire • 01/30/24
Annovis Bio Refines Timeline for Parkinson's Phase III Study Data AnnouncementGlobeNewsWire • 01/24/24
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's DiseaseGlobeNewsWire • 12/05/23